792 related articles for article (PubMed ID: 28895769)
1. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Walter E; Odin P
J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
[TBL] [Abstract][Full Text] [Related]
5. The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Chaudhuri KR; Pickard AS; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Bao Y; Sus J; Jones G; Ridley C; Oddsdottir J; Najle-Rahim S; Madin-Warburton M; Xu W; Schrag A
Pharmacoeconomics; 2022 May; 40(5):559-574. PubMed ID: 35307793
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Wirdefeldt K; Odin P; Nyholm D
CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
[TBL] [Abstract][Full Text] [Related]
8. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
9. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
10. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
[TBL] [Abstract][Full Text] [Related]
11. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
[TBL] [Abstract][Full Text] [Related]
12. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
Rudakova AV; Yakupov EZ
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):117-21. PubMed ID: 25614914
[TBL] [Abstract][Full Text] [Related]
14. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
[TBL] [Abstract][Full Text] [Related]
15. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Catalan MJ; Molina-Arjona JA; Mir P; Cubo E; Arbelo JM; Martinez-Martin P;
J Neurol; 2018 Jun; 265(6):1279-1287. PubMed ID: 29557989
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
[TBL] [Abstract][Full Text] [Related]
17. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
[TBL] [Abstract][Full Text] [Related]
19. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Groenendaal H; Tarrants ML; Armand C
Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
